Short Interest in Aeterna Zentaris Inc. (NASDAQ:AEZS) Drops By 22.1%

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) was the recipient of a significant decline in short interest in April. As of April 15th, there was short interest totalling 16,900 shares, a decline of 22.1% from the March 31st total of 21,700 shares. Based on an average daily volume of 15,900 shares, the short-interest ratio is presently 1.1 days. Currently, 0.4% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on shares of Aeterna Zentaris in a research note on Monday, April 22nd. They issued a “sell” rating for the company.

Aeterna Zentaris Stock Performance

NASDAQ AEZS opened at $1.95 on Friday. Aeterna Zentaris has a 1 year low of $1.36 and a 1 year high of $3.38. The company has a fifty day moving average of $1.98 and a two-hundred day moving average of $1.89.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its quarterly earnings data on Wednesday, March 27th. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.19). Aeterna Zentaris had a negative net margin of 368.01% and a negative return on equity of 63.20%. The company had revenue of $0.12 million during the quarter.

About Aeterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.